Other Biochemicals - Anlotinib Dihydrochloride （CAS: 1360460-82-7）

Anlotinib Dihydrochloride （CAS: 1360460-82-7）

Catalog #：EBC51559

Biological Activity

Synonyms

AL3818 dihydrochloride; AL-3818 dihydrochloride; AL 3818 dihydrochloride; Anlotinib HCl; AL3818; Anlotinib Dihydrochloride

Chemical Name

1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine;dihydrochloride

Application

Anlotinib Dihydrochloride (formerlyknown as AL3818 Dihydrochloride) is a novel and potent multi-kinase inhibitor that inhibits VEGFR2/3,FGFR1-4,PDGFRα/β,c-Kit, and Ret.

CAS Number

1360460-82-7

Purity

≥98.0%

Molecular Weight

480.36

Molecular Formula

C23H24CL2FN3O3

SMILES

CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC.Cl.Cl

Target & IC50

VEGFR2: IC50 = 0.2 nM
VEGFR3: IC50 = 0.7 nM
c-Kit: IC50 = 14.8 nM

Shipping

Gel Pack

Storage

Store at -20°C

Preparing Stock Solutions

Molecular Structure

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	2.0818 ml	10.4089 ml	20.8177 ml
5 mM	0.4164 ml	2.0818 ml	4.1635 ml
10 mM	0.2082 ml	1.0409 ml	2.0818 ml
50 mM	0.0416 ml	0.2082 ml	0.4164 ml

Solubility
DMSO: ≥ 60 mg/mL

Product Description

Anlotinib is a potential antineoplastic and anti-angiogenic receptor tyrosine kinase (RTK) inhibitor. Anlotinib dramatically lowers the number of AN3CA cells in vitro, which are identified by high levels of mutated FGFR2 protein expression. After a 29-day treatment cycle, daily oral administration of anlotinib (5 mg/kg) resulted in a complete response in 55% of treated animals and in a reduced tumor volume and tumor weights of AN3CA tumors by 94% and 96%, respectively. While paclitaxel and carboplatin were unable to stop the growth of the tumor, their combination with anlotinib did not appear to have a better result than Anlotinib treatment alone.